Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission

H. Oh, R. P. Gale, M. J. Zhang, J. R. Passweg, T. Ino, H. Murakami, R. Ohno, P. A. Rowlings, K. A. Sobocinski, M. Tanimoto, M. Tomonaga, D. J. Weisdorf, M. M. Horowitz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant Registry (IBMTR). Treatment-related mortality, relapse and leukemia-free survival were compared after adjusting for differences in subject- and disease-related variables and time-to-treatment. Outcomes differed in persons ≤ and > 30 years of age. Five-year treatment-related mortality in persons ≤ 30 years was 3% (95% confidence interval, 0-12%) with chemotherapy vs 32% (23-41%; P <0.0001) with transplants. The difference was greater among persons > 30 years, 13% (2-31%) with chemotherapy vs 57% (43-69%; P <0.0001) with transplants. Five-year relapse probability in persons ≤ 30 years was 69% (50-84%) with chemotherapy vs 22% (14-32%; P <0.0001) with transplants. Among persons > 30 years, 5-year relapse was 70% (53-85%) with chemotherapy vs 32% (20-45%; P <0.0001) with transplants. Leukemia-free survival at 5 years was significantly worse with chemotherapy than with transplants in persons ≤ 30 years (30% (15-48%) vs 53% (44-63%; P = 0.02)) but not in persons > 30 years (26% (13-41%) vs 30% (20-41%; P = 0.70)). We concluded that transplants result in more treatment-related deaths but fewer relapses than chemotherapy. Leukemia-free survival is better with transplants than chemotherapy in persons ≤ 30 years of age but comparable in older persons.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalBone Marrow Transplantation
Volume22
Issue number3
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Siblings
Bone Marrow
Transplants
Drug Therapy
Leukemia
Recurrence
Survival
Therapeutics
Mortality
Registries
Japan
Confidence Intervals
P-30 composite resin

Keywords

  • Bone marrow transplantation
  • Chemotherapy
  • Leukemia
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Oh, H., Gale, R. P., Zhang, M. J., Passweg, J. R., Ino, T., Murakami, H., ... Horowitz, M. M. (1998). Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplantation, 22(3), 253-257.

Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. / Oh, H.; Gale, R. P.; Zhang, M. J.; Passweg, J. R.; Ino, T.; Murakami, H.; Ohno, R.; Rowlings, P. A.; Sobocinski, K. A.; Tanimoto, M.; Tomonaga, M.; Weisdorf, D. J.; Horowitz, M. M.

In: Bone Marrow Transplantation, Vol. 22, No. 3, 1998, p. 253-257.

Research output: Contribution to journalArticle

Oh, H, Gale, RP, Zhang, MJ, Passweg, JR, Ino, T, Murakami, H, Ohno, R, Rowlings, PA, Sobocinski, KA, Tanimoto, M, Tomonaga, M, Weisdorf, DJ & Horowitz, MM 1998, 'Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission', Bone Marrow Transplantation, vol. 22, no. 3, pp. 253-257.
Oh, H. ; Gale, R. P. ; Zhang, M. J. ; Passweg, J. R. ; Ino, T. ; Murakami, H. ; Ohno, R. ; Rowlings, P. A. ; Sobocinski, K. A. ; Tanimoto, M. ; Tomonaga, M. ; Weisdorf, D. J. ; Horowitz, M. M. / Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. In: Bone Marrow Transplantation. 1998 ; Vol. 22, No. 3. pp. 253-257.
@article{d33cf3f395cf41d08ec32446bc8bc444,
title = "Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission",
abstract = "There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant Registry (IBMTR). Treatment-related mortality, relapse and leukemia-free survival were compared after adjusting for differences in subject- and disease-related variables and time-to-treatment. Outcomes differed in persons ≤ and > 30 years of age. Five-year treatment-related mortality in persons ≤ 30 years was 3{\%} (95{\%} confidence interval, 0-12{\%}) with chemotherapy vs 32{\%} (23-41{\%}; P <0.0001) with transplants. The difference was greater among persons > 30 years, 13{\%} (2-31{\%}) with chemotherapy vs 57{\%} (43-69{\%}; P <0.0001) with transplants. Five-year relapse probability in persons ≤ 30 years was 69{\%} (50-84{\%}) with chemotherapy vs 22{\%} (14-32{\%}; P <0.0001) with transplants. Among persons > 30 years, 5-year relapse was 70{\%} (53-85{\%}) with chemotherapy vs 32{\%} (20-45{\%}; P <0.0001) with transplants. Leukemia-free survival at 5 years was significantly worse with chemotherapy than with transplants in persons ≤ 30 years (30{\%} (15-48{\%}) vs 53{\%} (44-63{\%}; P = 0.02)) but not in persons > 30 years (26{\%} (13-41{\%}) vs 30{\%} (20-41{\%}; P = 0.70)). We concluded that transplants result in more treatment-related deaths but fewer relapses than chemotherapy. Leukemia-free survival is better with transplants than chemotherapy in persons ≤ 30 years of age but comparable in older persons.",
keywords = "Bone marrow transplantation, Chemotherapy, Leukemia, Treatment",
author = "H. Oh and Gale, {R. P.} and Zhang, {M. J.} and Passweg, {J. R.} and T. Ino and H. Murakami and R. Ohno and Rowlings, {P. A.} and Sobocinski, {K. A.} and M. Tanimoto and M. Tomonaga and Weisdorf, {D. J.} and Horowitz, {M. M.}",
year = "1998",
language = "English",
volume = "22",
pages = "253--257",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission

AU - Oh, H.

AU - Gale, R. P.

AU - Zhang, M. J.

AU - Passweg, J. R.

AU - Ino, T.

AU - Murakami, H.

AU - Ohno, R.

AU - Rowlings, P. A.

AU - Sobocinski, K. A.

AU - Tanimoto, M.

AU - Tomonaga, M.

AU - Weisdorf, D. J.

AU - Horowitz, M. M.

PY - 1998

Y1 - 1998

N2 - There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant Registry (IBMTR). Treatment-related mortality, relapse and leukemia-free survival were compared after adjusting for differences in subject- and disease-related variables and time-to-treatment. Outcomes differed in persons ≤ and > 30 years of age. Five-year treatment-related mortality in persons ≤ 30 years was 3% (95% confidence interval, 0-12%) with chemotherapy vs 32% (23-41%; P <0.0001) with transplants. The difference was greater among persons > 30 years, 13% (2-31%) with chemotherapy vs 57% (43-69%; P <0.0001) with transplants. Five-year relapse probability in persons ≤ 30 years was 69% (50-84%) with chemotherapy vs 22% (14-32%; P <0.0001) with transplants. Among persons > 30 years, 5-year relapse was 70% (53-85%) with chemotherapy vs 32% (20-45%; P <0.0001) with transplants. Leukemia-free survival at 5 years was significantly worse with chemotherapy than with transplants in persons ≤ 30 years (30% (15-48%) vs 53% (44-63%; P = 0.02)) but not in persons > 30 years (26% (13-41%) vs 30% (20-41%; P = 0.70)). We concluded that transplants result in more treatment-related deaths but fewer relapses than chemotherapy. Leukemia-free survival is better with transplants than chemotherapy in persons ≤ 30 years of age but comparable in older persons.

AB - There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant Registry (IBMTR). Treatment-related mortality, relapse and leukemia-free survival were compared after adjusting for differences in subject- and disease-related variables and time-to-treatment. Outcomes differed in persons ≤ and > 30 years of age. Five-year treatment-related mortality in persons ≤ 30 years was 3% (95% confidence interval, 0-12%) with chemotherapy vs 32% (23-41%; P <0.0001) with transplants. The difference was greater among persons > 30 years, 13% (2-31%) with chemotherapy vs 57% (43-69%; P <0.0001) with transplants. Five-year relapse probability in persons ≤ 30 years was 69% (50-84%) with chemotherapy vs 22% (14-32%; P <0.0001) with transplants. Among persons > 30 years, 5-year relapse was 70% (53-85%) with chemotherapy vs 32% (20-45%; P <0.0001) with transplants. Leukemia-free survival at 5 years was significantly worse with chemotherapy than with transplants in persons ≤ 30 years (30% (15-48%) vs 53% (44-63%; P = 0.02)) but not in persons > 30 years (26% (13-41%) vs 30% (20-41%; P = 0.70)). We concluded that transplants result in more treatment-related deaths but fewer relapses than chemotherapy. Leukemia-free survival is better with transplants than chemotherapy in persons ≤ 30 years of age but comparable in older persons.

KW - Bone marrow transplantation

KW - Chemotherapy

KW - Leukemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031853347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031853347&partnerID=8YFLogxK

M3 - Article

C2 - 9720738

AN - SCOPUS:0031853347

VL - 22

SP - 253

EP - 257

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -